May 6, 2019
Editor's Note: An original headline for this story contained an error, and has since been corrected.
Boston- and San Francisco-based Pear Therapeutics, maker of prescription digital therapeutics for substance abuse, has kicked off a feasibility study for Pear-006, an in-development treatment for depressive symptoms in those with multiple sclerosis (MS).
Pear Therapeutics has been developing Pear-...
April 9, 2019
Although still in its earliest chapters, the story of digital thherapeutics is beginning to pick up steam. Just six months ago, that the first software-only therapeutic cleared by the FDA, Pear Therapeutics’ reSET, kicked off a commercial launch driven by the sales channels expertise of an established pharmaceutical partner.
Proteus, meanwhile, recently expanded dealings with its long-time pharma...
April 4, 2019
Figuring out the best user experience can be a tricky process for any platform. But its particularly important in digital therapeutics, which some view as a disruptor to traditional pharmaceuticals.
Unlike medical drug makers, digital therapeutics companies have UX design to consider during the development of their products, Madhavi Jagdish, director of product designer at Pear Therapeutics,...
January 7, 2019
On Friday Boston-based Pear Therapeutics announced a whopping $64 million Series C funding. The latest financing was led by Temasek, with participation from Novartis, 5AM Ventures, Arboretum Ventures, Jazz Venture Partners, The Bridge Builders Collaborative and EDBI.
This announcement comes just one year after the digital therapeutic maker landed $50 million in Series B funding.
What they do...
December 10, 2018
The FDA has officially cleared reSET-O — a digital therapeutic to treat opioid use disorder (OUD) jointly developed by Pear Therapeutics and Sandoz, a division of Novartis — a little over a year after it was granted an Expedited Access Pathway designation from the agency.
This announcement makes reSET-O the first digital therapeutic to treat patients with OUD. Patients will need a valid...
Novartis' recently-opened digital health innovation lab in San Francisco. Photo courtesy Novartis on Twitter.
November 21, 2018
Last month, Novartis announced that it would be cutting 2,200 jobs as part of a restructuring of the company focusing on particular priorities.
“The overall strategy we have is to focus the company as a leading medicines company powered by digital technologies,” CEO Vas Narasimhan told STAT News last month. “What that has meant is to exit certain health care sectors or segments … — so we exited...
November 20, 2018
reSET — a substance use disorder treatment that was the first software-only therapeutic cleared by the FDA — is now commercially available for clinicians to prescribe to their patients, according to a release from Pear Therapeutics and Sandoz, a division of Novartis with which Pear partnered back in April.
But while physical prescription drugs are usually handled through a pharmacy, the process...
The digital health landscape, from the Digital Therapeutics Alliance's new report.
October 31, 2018
The precise definition of digital therapeutics has been a hot topic as the new technology category has been discussed and debated in event sessions and articles over the last few years. Now the Digital Therapeutics Alliance, a consortium of industry stakeholders, is hoping to put that to rest with an official definition, released this week in a whitepaper.
The definition reads as follows:
(L to R) Moderator Scott Thiel, Pear Therapeutics' Dan Amor, Verily's Afia Asamoah, Tidepool's Howard Look, and Johnson & Johnson's Eduardo Sanchez (photo by Jonah Comstock)
October 19, 2018
Attendees to the Connected Health Conference in Boston this week got a sneak peek into the workings of the FDA's much-discussed Pre-Cert program. In a panel discussion at the event, representatives from Verily, Pear Therapeutics, Tidepool, and Johnson & Johnson candidly discussed their experiences so far with the program, describing an evolving process that is collaborative and rigorous.
October 15, 2018
As digital therapeutics move to cross boundaries of regulatory approval and efficacy data, the healthcare industry will begin to move to a bifurcated world of digital health apps in the same way that drugs are now divided up into largely unregulated supplements and heavily regulated pharmaceuticals.
At the Digital Health Innovation Summit last week in Boston, Sanofi Ventures Senior Director of...